Institute of Pharmaceutical Chemistry, Philipps University, Marbacher Weg 6, 35032, Marburg, Germany.
Lee Kong Chian School of Medicine, Nanyang Technological University, EMB 03-07, 59 Nanyang Drive, Singapore, 636921, Singapore.
ChemMedChem. 2020 Aug 5;15(15):1439-1452. doi: 10.1002/cmdc.202000237. Epub 2020 Jun 30.
A series of cyclic active-site-directed inhibitors of the NS2B-NS3 proteases from Zika (ZIKV), West Nile (WNV), and dengue-4 (DENV4) viruses has been designed. The most potent compounds contain a reversely incorporated d-lysine residue in the P1 position. Its side chain is connected to the P2 backbone, its α-amino group is converted into a guanidine to interact with the conserved Asp129 side chain in the S1 pocket, and its C terminus is connected to the P3 residue via different linker segments. The most potent compounds inhibit the ZIKV protease with K values <5 nM. Crystal structures of seven ZIKV protease inhibitor complexes were determined to support the inhibitor design. All the cyclic compounds possess high selectivity against trypsin-like serine proteases and furin-like proprotein convertases. Both WNV and DENV4 proteases are inhibited less efficiently. Nonetheless, similar structure-activity relationships were observed for these enzymes, thus suggesting their potential application as pan-flaviviral protease inhibitors.
已设计出一系列针对 Zika(ZIKV)、西尼罗河(WNV)和登革热 4 型(DENV4)病毒的 NS2B-NS3 蛋白酶的环状活性位点导向抑制剂。最有效的化合物在 P1 位置包含一个反向掺入的 d-赖氨酸残基。其侧链连接到 P2 主链,其α-氨基被转化为胍,与 S1 口袋中保守的 Asp129 侧链相互作用,其 C 末端通过不同的连接子片段与 P3 残基连接。最有效的化合物以 K 值 <5 nM 抑制 ZIKV 蛋白酶。已确定七个 ZIKV 蛋白酶抑制剂复合物的晶体结构以支持抑制剂设计。所有环状化合物对胰凝乳蛋白酶样丝氨酸蛋白酶和类枯草杆菌蛋白酶原转化酶具有高选择性。WNV 和 DENV4 蛋白酶的抑制效率较低。尽管如此,这些酶观察到相似的构效关系,因此表明它们有潜力作为泛黄病毒蛋白酶抑制剂应用。